BioRestorative Therapies, Inc. BRTX
1.56 USD +0.01 (+0.65%)
At closeNov 11, 2026, 7:24 PM EST
1.40 -0.16 -10.26%
After hours · Nov 11, 7:24 PM ET
1.51 Day range 1.59
1.28 52-week range 28.99
- YTD
- +33.33%
- 1 year
- +10.64%
News
defenseworld.net Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update Biorestorative Therapies, Inc. (NASDAQ: BRTX - Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
benzinga.com Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
benzinga.com BioRestorative Therapies Announces 1-For-20 Reverse Stock Split BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a
globenewswire.com BioRestorative Therapies Announces Reverse Stock Split MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today…
benzinga.com Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product Lines On August 7, 2026, BioRestorative Therapies, Inc. (the "Company") suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
benzinga.com BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFO https://ir.biorestorative.com/sec-filings/all-sec-filings/content/0001493152-26-033593/form8-k.htm
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
benzinga.com BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc Disease BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products,
globenewswire.com BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company…
globenewswire.com BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, energy down 1.9%. DKS stock falls 5% on mixed results.
benzinga.com Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms Undisclosed Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholdersMIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge…
prnewswire.com Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based…- benzinga.com BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today…
globenewswire.com BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
zacks.com What Makes Biorestorative Therapies (BRTX) a New Buy Stock Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.56 per share a year ago.
benzinga.com BioRestorative Therapies Presents Data Showing MSC-Derived Exosomes Have Source-Specific Functional Signatures For Targeted Therapeutic Applications At The International Society For Cell & Gene Therapy 2026 Annual Meeting Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applicationsMELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N. Y. , May 13, 2026 (GLOBE NEWSWIRE)…
benzinga.com BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no…
globenewswire.com BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no…
benzinga.com BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today…
globenewswire.com BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:…
zacks.com Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong…
globenewswire.com BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across…
globenewswire.com BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare- benzinga.com BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today…
globenewswire.com BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem…
zacks.com Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.2 per share a year ago.
benzinga.com BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 60 percent decrease over losses…- benzinga.com BioRestorative Therapies To Present Data On ~45 Participants From Its Phase 2 Clinical Study Of Hypoxic-cultured Mesenchymal Stem Cells To Treat Chronic Lumbar Disc Disease BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today…
globenewswire.com BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
globenewswire.com BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session